Sign inJoin waitlistJoin the waitlist

MD

Mark Dickson

Associate Attending Physician · New York Presbyterian Hospital

Credentials: · · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2006–2008
New York Presbyterian Hospital
2003–2006
Columbia Univ Coll of Phys & Surgeons
1999–2003

Research

Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation…
Molecular and Cellular Biology · 2000 · First of 9 authors · 980 citations
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at…
Journal of Clinical Oncology · 2015 · 858 citations
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Journal of Clinical Oncology · 2019 · 523 citations

WT
William Tap
51 papers
SD
Sandra D'Angelo
46 papers · 16 as a resident
MK
Mary Keohan
44 papers
Mrinal Gounder
41 papers
Gary Schwartz
35 papers
PC
Ping Chi
34 papers
Samuel Singer
33 papers · 3 as a fellow
CA
Cristina Antonescu
31 papers
CK
Ciara Kelly
28 papers
Sujana Movva
24 papers
ER
Evan Rosenbaum
23 papers · 3 as a fellow
AC
Aimee Crago
20 papers

Clinical trials

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Principal investigator · Active not recruiting · Phase 3
Sarcoma Alliance for Research through Collaboration
2021–2026
Study of Abemaciclib in Dedifferentiated Liposarcoma
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2016–2027
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2012
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2010–2016